Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023

SELL
$0.0 - $0.18 $0 - $1,609
-8,941 Reduced 92.23%
753 $0
Q4 2022

Feb 13, 2023

SELL
$0.14 - $12.49 $6,966 - $621,539
-49,763 Reduced 83.7%
9,694 $1,000
Q3 2022

Nov 03, 2022

BUY
$8.51 - $13.6 $353,241 - $564,522
41,509 Added 231.27%
59,457 $623,000
Q2 2022

Aug 12, 2022

BUY
$7.31 - $11.85 $12,215 - $19,801
1,671 Added 10.27%
17,948 $174,000
Q4 2021

Feb 14, 2022

SELL
$4.19 - $9.56 $16,659 - $38,010
-3,976 Reduced 19.63%
16,277 $156,000
Q3 2021

Nov 09, 2021

BUY
$3.56 - $4.64 $38,209 - $49,801
10,733 Added 112.74%
20,253 $94,000
Q2 2021

Aug 13, 2021

SELL
$3.95 - $5.41 $104,959 - $143,754
-26,572 Reduced 73.62%
9,520 $40,000
Q1 2021

May 13, 2021

BUY
$4.52 - $7.8 $65,756 - $113,474
14,548 Added 67.53%
36,092 $191,000
Q4 2020

Feb 11, 2021

BUY
$4.37 - $9.46 $2,962 - $6,413
678 Added 3.25%
21,544 $153,000
Q3 2020

Nov 12, 2020

SELL
$8.56 - $26.93 $421,152 - $1.32 Million
-49,200 Reduced 70.22%
20,866 $189,000
Q2 2020

Aug 12, 2020

BUY
$21.21 - $31.55 $792,935 - $1.18 Million
37,385 Added 114.39%
70,066 $1.93 Million
Q1 2020

May 13, 2020

SELL
$18.43 - $38.04 $113,197 - $233,641
-6,142 Reduced 15.82%
32,681 $718,000
Q4 2019

Feb 10, 2020

BUY
$29.6 - $43.71 $519,065 - $766,498
17,536 Added 82.38%
38,823 $1.47 Million
Q3 2019

Nov 14, 2019

BUY
$29.87 - $42.22 $154,069 - $217,770
5,158 Added 31.98%
21,287 $657,000
Q2 2019

Aug 14, 2019

BUY
$31.16 - $39.46 $274,021 - $347,011
8,794 Added 119.89%
16,129 $636,000
Q1 2019

May 15, 2019

BUY
$19.96 - $38.62 $3,173 - $6,140
159 Added 2.22%
7,335 $283,000
Q4 2018

Feb 14, 2019

BUY
$23.57 - $32.33 $21,354 - $29,290
906 Added 14.45%
7,176 $169,000
Q3 2018

Nov 14, 2018

BUY
$22.5 - $39.35 $120,825 - $211,309
5,370 Added 596.67%
6,270 $192,000
Q2 2018

Aug 14, 2018

BUY
$26.0 - $29.9 $23,400 - $26,910
900 New
900 $27,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.